ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Hisamitsu Pharmaceutical Co., Inc.

Business Summary

Hisamitsu Pharmaceutical Co., Inc. engages in the research, development, manufacture, and sale of pharmaceuticals and related products. Its products are sold under Salonpas, Salonsip, Mohrus, ByeBye-Fever, and Keplat brands. It also provides ethical pharmaceuticals, over- the-counter drugs, medical devices, health supplements, and topical analgesic products. The company was founded by Nihei Hisamitsu in 1847 and is headquartered in Tosu, Japan.

Financial Highlights

Feb 2021 JPYUSD
Revenue114,510M1,080.68M
Gross Profit69,173M652.81M
Operating income10,672M100.71M
Income before tax12,197M115.10M
Net income9,251M87.30M
EBITDA14,751M139.21M
Diluted EPS113.101.06
Dividends Per Share83.500.78
Total Assets299,861M2,814.53M
Total liabilities46,048M432.21M
Total equity252,299M2,368.11M
Operating cash flow5,289M49.91M
Currency in JPYCurrency in USD

Historical Data

 Feb 2017Feb 2018Feb 2019Feb 2020Feb 2021
Revenue 145,925M 147,870M 143,408M 140,992M 114,510M
Gross Profit 91,840M 92,182M 88,681M 87,604M 69,173M
Operating income 26,306M 26,346M 22,280M 22,729M 10,672M
Income before tax 29,984M 27,694M 25,673M 26,155M 12,197M
Net income 20,395M 19,120M 19,204M 18,694M 9,251M
EBITDA 33,674M 32,351M 28,022M 26,980M 14,751M
Diluted EPS 241.14 228.34 229.85 227.29 113.10
Dividends Per Share 81.50 82 82.50 83 83.50
Total Assets 278,820M 299,913M 295,786M 307,401M 299,861M
Total liabilities 49,611M 54,681M 47,154M 56,652M 46,048M
Total equity 228,108M 244,000M 247,334M 249,276M 252,299M
Operating cash flow 19,910M 30,453M 15,772M 27,395M 5,289M
 Feb 2017Feb 2018Feb 2019Feb 2020Feb 2021
Revenue 1,347.79M 1,327.30M 1,298.05M 1,293.38M 1,080.68M
Gross Profit 848.25M 827.44M 802.69M 803.63M 652.81M
Operating income 242.96M 236.48M 201.66M 208.50M 100.71M
Income before tax 276.93M 248.58M 232.37M 239.93M 115.10M
Net income 188.37M 171.62M 173.82M 171.48M 87.30M
EBITDA 311.02M 290.38M 253.63M 247.50M 139.21M
Diluted EPS 2.22 2.04 2.08 2.08 1.06
Dividends Per Share 0.75 0.73 0.74 0.76 0.78
Total Assets 2,492.02M 2,810.67M 2,657.07M 2,849.86M 2,814.53M
Total liabilities 443.41M 512.45M 423.58M 525.21M 432.21M
Total equity 2,038.77M 2,286.67M 2,221.82M 2,310.99M 2,368.11M
Operating cash flow 183.89M 273.35M 142.75M 251.30M 49.91M

Valuation Measures

Feb 2021
PER58.65
ROA3.04%
ROE3.68%
Operating margin9.31%
Profit margin8.07%

Key executives

  • President & Representative Director: Kazuhide Nakatomi
  • Director, Executive Officer, Manager-Finance & IR: Shinichiro Takao
  • Senior Executive Officer, GM-R&D: Takaaki Terahara
  • Director, Manager-Legal Affairs & Head-Compliance: Nobuo Tsutsumi
  • MD, Executive Officer & Head-Operations: Tetsuo Akiyama

Shareholders

  • Government of Japan (5.7%)
  • Nishi Nippon City Bank Pension Fund (5.1%)
  • Bank of Tokyo Mitsubishi UFJ Pension Fund (5.0%)
  • Nippon Life Insurance Co. (4.5%)
  • Hisamitsu Pharmaceutical Co., Inc. (3.9%)
  • Fukuoka Financial Group, Inc. (3.9%)
  • The Bank of Saga Ltd. (2.7%)
  • Hisamitsu Pharmaceutical Business Association (2.7%)
  • Sumitomo Mitsui Banking Pension Fund (2.4%)
  • Mitsubishi UFJ Financial Group, Inc. (2.1%)

Contact Details

Related Companies

  • Hisamitsu Italia Srl
  • Hisamitsu Agency Co., Ltd
  • Hisamitsu Pharmaceutical (Hong Kong) Co., Ltd.
  • Hisamitsu Pharmaceutical (China) Co., Ltd.
  • Nakatomi Memorial Foundation
  • Hisamitsu Pharmaceutical Co., Ltd
  • Hisamitsu Farmaceutica do Brasil Ltda.
  • Hisamitsu Vietnam Pharmaceutical Co., Ltd.
  • PT Hisamitsu Pharma Indonesia
  • Hisamitsu UK Ltd.
  • Hisamitsu Pharmaceutical Business Association
  • Hisamitsu Pharmaceutical Tech Consulting (Beijing) Co., Ltd.
  • CRCC Media Co., Ltd.
  • Hisamitsu America, Inc.
  • Saga City-Vision Co., Ltd.
  • Hisamitsu U.S., Inc.
  • SSP Co. Ltd. /Ethical Medicine Division/
  • Taiyo Co., Ltd
  • Noven Pharmaceuticals, Inc.

Competitors

  • DURECT Corporation
  • KemPharm, Inc.
  • Icure Pharmaceutical Inc.
  • Zosano Pharma Corp.
Last Updated on 24 Sep, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more